Critical Infrastructure Investments to carry operations forward in UK and Singapore

Two new investments announced by Astrea Bioseparations, include the addition of two new laboratories to the company’s R&D facility in Cambridge, UK and a branch office registered in Singapore to serve customers in Asia.

Claire Dacombe, PhD was appointed as Vice President of Asia Pacific Operations.

 “The Cambridge laboratory expansion was a first step in bolstering capacity to meet growing demand for Astrea Bioseparations products and services. New dedicated column packing space was constructed to increase capacity for pre-packed column development and support,” said Dr Steve Burton, President & CSO at Astrea. “A new Biosafety Level 2 (BSL-2) laboratory has facilitated work with pathogenic materials of relevance for viral vector, virus and prion projects. Pursuant to the December 2020 license agreement with AVACTA, we have also dedicated new laboratory space for Affimer® ligand discovery and development work.”

“This is an exciting time as we continue to evolve our commercial strategy with a focus on reliability of supply and quality of products and services. With market demand increasing in Asia, it became clear that it would benefit our customers to have a local presence in Singapore,” Gabe Longoria, CCO said. “We are thrilled to have Claire Dacombe join Astrea Bioseparations with extensive expertise in high level distribution, sales, and operations activities across the Asia Pacific region.” 

More information online